...Apellis Pharmaceuticals' Empaveli as a first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare and deadly chronic blood disorder. The biotech said it will initially target patients that have not responded to Soliris and/or Ultomiris, both C5 inhibitors from Alexion Pharmaceuticals. Under the pharmacy benefit, Soliris holds covered or better status for 53% of all covered lives. It is not covered for 26.3% of all lives.
SOURCE: MMIT Analytics, as of 5/19/21
No comments:
Post a Comment